转移性肾细胞癌靶向治疗进展

Progress in targeted therapy for metastatic renal cell carcinoma

近年来,随着人们对肾细胞癌发病机制研究的不断深入,产生了抗VEGF受体抑制剂和mTOR抑制剂,使得转移性肾细胞癌进入靶向治疗时代。本文对国内外最新研究结果进行分析,对于转移性肾细胞癌患者,靶向药物首选舒尼替尼和培唑帕尼,药物剂量从标准剂量开始,疾病进展时,可酌情增量;出现不良反应时,应及时对症处理或减量。使用抗VEGF抑制剂时,应密切监测患者血压,当患者血糖较高或患有糖尿病时,应首选抗VEGF抑制剂。

In recent years,with the deepening of research on the pathogenesis of renal cell carcinoma,anti-VEGF receptor inhibitors and mTOR inhibitors have been produced,making metastatic renal cell car CI noma into the era of targeted therapy.This article analyzed the latest research results at home and abroad.For patients with metastatic renal cell carcinoma,sunitinib and pizopanib are the first choice for targeted drugs.The drug dose starts from the standard dose,and the disease can be increased as appropriate when the disease progresses;When responding,it should be treated or reduced in time.When using an anti-VEGF inhibitor,the patient's blood pressure should be closely monitored.When the patient has high blood sugar or diabetes,anti-VEGF inhibitors should be preferred.